The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 19, 2022
Filed:
Apr. 22, 2021
Applicant:
Crispr Therapeutics Ag, Zug, CH;
Inventors:
Mark Benton, Cambridge, MA (US);
Tony Ho, Cambridge, MA (US);
Demetrios Kalaitzidis, Cambridge, MA (US);
Ewelina Morawa, Cambridge, MA (US);
Jonathan Alexander Terrett, Cambridge, MA (US);
Assignee:
CRISPR Therapeutics AG, Zug, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61P 35/00 (2006.01); C12N 15/85 (2006.01); C07K 16/28 (2006.01); A61K 48/00 (2006.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01); C07K 14/725 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 48/005 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 16/2866 (2013.01); C12N 5/0636 (2013.01); C12N 15/85 (2013.01); A61K 2039/505 (2013.01); C12N 2510/00 (2013.01);
Abstract
A population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and contain a disrupted TRAC gene, a disrupted B2M gene, or both, for use in treating a B cell malignancy.